Aortic stenosis (AS or AoS) is the narrowing of the exit of the left ventricle of the heart (where the aorta begins), such that problems result. It may occur at the aortic valve as well as above and below this level. It typically gets worse over time. Symptoms often come on gradually with a decreased ability to exercise often occurring first. If heart failure, loss of consciousness, or heart related chest pain occurs due to AS the outcomes are worse. Loss of consciousness typically occurs with standing or exercise. Signs of heart failure include shortness of breath especially when lying down, at night, or with exercise, and swelling of the legs. Thickening of the valve without narrowing is known as aortic sclerosis.
|In the center an aortic valve with severe stenosis due to rheumatic heart disease. The valve is surrounded by the aorta. The pulmonary trunk is at the lower right. The right coronary artery, cut lengthwise, is at the lower left. The left main coronary artery, also cut lengthwise, is on the right.|
|Symptoms||Decreased ability to exercise, loss of consciousness, shortness of breath, heart related chest pain, leg swelling|
|Causes||Bicuspid aortic valve, rheumatic fever|
|Risk factors||Smoking, high blood pressure, high cholesterol, diabetes, being male|
|Diagnostic method||Ultrasound of the heart|
|Treatment||Valve replacement surgery, balloon aortic valvuloplasty|
|Prognosis||Five-year survival ~50% without treatment|
|Frequency||2% of people over 65 (developed world)|
Causes include being born with a bicuspid aortic valve, and rheumatic fever. A bicuspid aortic valve affects about one to two percent of the population. As of 2014 rheumatic heart disease mostly occurs in the developing world. A normal valve may also harden over the decades. Risk factors are similar to those of coronary artery disease and include smoking, high blood pressure, high cholesterol, diabetes, and being male. The aortic valve usually has three leaflets and is located between the left ventricle of the heart and the aorta. AS typically results in a heart murmur. Its severity can be divided into mild, moderate, severe, and very severe, distinguishable by ultrasound of the heart.
Aortic stenosis is typically followed using repeated ultrasound scans. Once it has become severe, treatment primarily involves valve replacement surgery, with transcatheter aortic valve replacement (TAVR) being an option in some who are at high risk from surgery. Valves may either be mechanical or bioprosthetic, with each having risks and benefits. Another less invasive procedure, balloon aortic valvuloplasty (BAV), may result in benefit, but for only a few months. Complications such as heart failure may be treated in the same way as in those with mild to moderate AS. In those with severe disease a number of medications should be avoided, including ACE inhibitors, nitroglycerin, and some beta blockers. Nitroprusside or phenylephrine may be used in those with decompensated heart failure depending on the blood pressure.
Aortic stenosis is the most common valvular heart disease in the developed world. It affects about 2% of people who are over 65 years of age. Estimated rates were not known in most of the developing world as of 2014. In those who have symptoms, without repair the chance of death at five years is about 50% and at 10 years is about 90%. Aortic stenosis was first described by French physician Lazare Rivière in 1663.
Signs and symptomsEdit
Symptoms related to aortic stenosis depend on the degree of stenosis. Most people with mild to moderate aortic stenosis do not have symptoms. Symptoms usually present in individuals with severe aortic stenosis, though they may also occur in those with mild to moderate aortic stenosis. The three main symptoms of aortic stenosis are loss of consciousness, anginal chest pain and shortness of breath with activity or other symptoms of heart failure such as shortness of breath while lying flat, episodes of shortness of breath at night, or swollen legs and feet. It may also be accompanied by the characteristic "Dresden china" appearance of pallor with a light flush.
Angina in setting of heart failure also increases the risk of death. In people with angina, the 5-year mortality rate is 50% if the aortic valve is not replaced.
Angina in the setting of AS occurs due to left ventricular hypertrophy (LVH) that is caused by the constant production of increased pressure required to overcome the pressure gradient caused by the AS. While the muscular layer of the left ventricle thickens, the arteries that supply the muscle do not get significantly longer or bigger, so the muscle may not receive enough blood supply to meet its oxygen requirement. This ischemia may first be evident during exercise when the heart muscle requires increased blood supply to compensate for the increased workload. The individual may complain of anginal chest pain with exertion. At this stage, a cardiac stress test with imaging may be suggestive of ischemia.
Eventually, however, the heart muscle will require more blood supply at rest than can be supplied by the coronary artery branches. At this point there may be signs of ventricular strain pattern (ST segment depression and T wave inversion) on the EKG, suggesting subendocardial ischemia. The subendocardium is the region that is most susceptible to ischemia because it is the most distant from the epicardial coronary arteries.
Syncope (fainting spells) from aortic valve stenosis is usually exertional. In the setting of heart failure it increases the risk of death. In people with syncope, the three-year mortality rate is 50% if the aortic valve is not replaced.
It is unclear why aortic stenosis causes syncope. One popular theory is that severe AS produces a nearly fixed cardiac output. When a person with aortic stenosis exercises, their peripheral vascular resistance will decrease as the blood vessels of the skeletal muscles dilate to allow the muscles to receive more blood to allow them to do more work. This decrease in peripheral vascular resistance is normally compensated for by an increase in the cardiac output. Since people with severe AS cannot increase their cardiac output, the blood pressure falls and the person will faint due to decreased blood perfusion to the brain.
A second theory as to why syncope may occur in AS is that during exercise, the high pressures generated in the hypertrophied left ventricle cause a vasodepressor response, which causes a secondary peripheral vasodilation that, in turn, causes decreased blood flow to the brain resulting in loss of consciousness. Indeed, in aortic stenosis, because of the fixed obstruction to blood flow out from the heart, it may be impossible for the heart to increase its output to offset peripheral vasodilation.
A third mechanism may sometimes be operative. Due to the hypertrophy of the left ventricle in aortic stenosis, including the consequent inability of the coronary arteries to adequately supply blood to the myocardium (see "Angina" below), abnormal heart rhythms may develop. These can lead to syncope.
Finally, in calcific aortic stenosis at least, the calcification in and around the aortic valve can progress and extend to involve the electrical conduction system of the heart. If that occurs, the result may be heart block, a potentially lethal condition of which syncope may be a symptom.
Congestive heart failureEdit
Congestive heart failure (CHF) carries a grave prognosis in people with AS. People with CHF attributable to AS have a 2-year mortality rate of 50% if the aortic valve is not replaced. CHF in the setting of AS is due to a combination of left ventricular hypertrophy with fibrosis, systolic dysfunction (a decrease in the ejection fraction) and diastolic dysfunction (elevated filling pressure of the LV).
In Heyde's syndrome, aortic stenosis is associated with gastrointestinal bleeding due to angiodysplasia of the colon. Recent research has shown that the stenosis causes a form of von Willebrand disease by breaking down its associated coagulation factor (factor VIII-associated antigen, also called von Willebrand factor), due to increased turbulence around the stenotic valve.
Notwithstanding the foregoing, the American Heart Association has recently changed its recommendations regarding antibiotic prophylaxis for endocarditis. Specifically, as of 2007 it is recommended that such prophylaxis should be limited only to those with prosthetic heart valves, those with previous episode(s) of endocarditis, and those with certain types of congenital heart disease.
Since the stenosed aortic valve may limit the heart's output, people with aortic stenosis are at risk of syncope and dangerously low blood pressure should they use any of a number of medications for cardiovascular diseases that often coexist with aortic stenosis. Examples include nitroglycerin, nitrates, ACE inhibitors, terazosin (Hytrin), and hydralazine. Note that all of these substances lead to peripheral vasodilation. Under normal circumstances, in the absence of aortic stenosis, the heart is able to increase its output and thereby offset the effect of the dilated blood vessels. In some cases of aortic stenosis, however, due to the obstruction of blood flow out of the heart caused by the stenosed aortic valve, cardiac output cannot be increased. Low blood pressure or syncope may ensue.
Aortic stenosis is most commonly caused by age-related progressive calcification (>50% of cases), with a mean age of 65 to 70 years. Another major cause of aortic stenosis is the calcification of a congenital bicuspid aortic valve (30-40% of cases), typically presenting earlier in those aged 40+ to 50+.
Acute rheumatic fever post-inflammatory is the cause of less than 10% of cases. Rare causes of aortic stenosis include Fabry disease, systemic lupus erythematosus, Paget disease, high blood uric acid levels, and infection.
The human aortic valve normally consists of three cusps or leaflets and has an opening of 3.0-4.0 square centimeters. When the left ventricle contracts, it forces blood through the valve into the aorta and subsequently to the rest of the body. When the left ventricle expands again, the aortic valve closes and prevents the blood in the aorta from flowing backward (regurgitation) into the left ventricle. In aortic stenosis, the opening of the aortic valve becomes narrowed or constricted (stenotic) (e.g., due to calcification). Degenerative (the most common variety), and bicuspid aortic stenosis both begin with damage to endothelial cells from increased mechanical stress. Inflammation is thought to be involved in the earlier stages of the pathogenesis of AS and its associated risk factors are known to promote the deposition of LDL cholesterol and lipoprotein(a), a highly damaging substance, into the aortic valve, causing significant damage and stenosis over time.
As a consequence of this stenosis, the left ventricle must generate a higher pressure with each contraction to effectively move blood forward into the aorta. Initially, the LV generates this increased pressure by thickening its muscular walls (myocardial hypertrophy). The type of hypertrophy most commonly seen in AS is known as concentric hypertrophy, in which the walls of the LV are (approximately) equally thickened.
In the later stages, the left ventricle dilates, the wall thins, and the systolic function deteriorates (resulting in impaired ability to pump blood forward). Morris and Innasimuthu et al. showed that different coronary anatomy is associated with different valve diseases. Research is ongoing to see if different coronary anatomy might lead to turbulent flow at the level of valves leading to inflammation and degeneration.
Aortic stenosis is most often diagnosed when it is asymptomatic and can sometimes be detected during routine examination of the heart and circulatory system. Good evidence exists to demonstrate that certain characteristics of the peripheral pulse can rule in the diagnosis. In particular, there may be a slow and/or sustained upstroke of the arterial pulse, and the pulse may be of low volume. This is sometimes referred to as pulsus parvus et tardus. There may also be a noticeable delay between the first heart sound (on auscultation) and the corresponding pulse in the carotid artery (so-called 'apical-carotid delay'). In a similar manner, there may be a delay between the appearance of each pulse in the brachial artery (in the arm) and the radial artery (in the wrist).
The first heart sound may be followed by a sharp ejection sound ("ejection click") best heard at the lower left sternal border and the apex, and, thus, appear to be "split". The ejection sound, caused by the impact of left ventricular outflow against the partially fused aortic valve leaflets, is more commonly associated with a mobile bicuspid aortic valve than an immobile calcified aortic valve. The intensity of this sound does not vary with respiration, which helps distinguish it from the ejection click produced by a stenotic pulmonary valve, which will diminish slightly in intensity during inspiration.
An easily heard systolic, crescendo-decrescendo (i.e., 'ejection') murmur is heard loudest at the upper right sternal border, at the 2nd right intercostal space, and radiates to the carotid arteries bilaterally. The murmur increases with squatting and decreases with standing and isometric muscular contraction such as the Valsalva maneuver, which helps distinguish it from hypertrophic obstructive cardiomyopathy (HOCM). The murmur is louder during expiration but is also easily heard during inspiration. The more severe the degree of the stenosis, the later the peak occurs in the crescendo-decrescendo of the murmur.
The second heart sound (A2) tends to become decreased and softer as the aortic stenosis becomes more severe. This is a result of the increasing calcification of the valve preventing it from "snapping" shut and producing a sharp, loud sound. Due to increases in left ventricular pressure from the stenotic aortic valve, over time the ventricle may hypertrophy, resulting in a diastolic dysfunction. As a result, there may be a fourth heart sound due to the stiff ventricle. With continued increases in ventricular pressure, dilatation of the ventricle will occur, and a third heart sound may be manifest.
Finally, aortic stenosis often co-exists with some degree of aortic insufficiency (aortic regurgitation). Hence, the physical exam in aortic stenosis may also reveal signs of the latter, for example, an early diastolic decrescendo murmur. Indeed, when both valve abnormalities are present, the expected findings of either may be modified or may not even be present. Rather, new signs that reflect the presence of simultaneous aortic stenosis and insufficiency, e.g., pulsus bisferiens, emerge.
According to a meta-analysis, the most useful findings for ruling in aortic stenosis in the clinical setting were slow rate of rise of the carotid pulse (positive likelihood ratio ranged 2.8–130 across studies), mid to late peak intensity of the murmur (positive likelihood ratio, 8.0–101), and decreased intensity of the second heart sound (positive likelihood ratio, 3.1–50).
Other peripheral signs include:
- sustained, heaving apex beat, which is not displaced unless systolic dysfunction of the left ventricle has developed
- A precordial thrill
- narrowed pulse pressure
Although aortic stenosis does not lead to any specific findings on the electrocardiogram (ECG), it still often leads to a number of electrocardiographic abnormalities. ECG manifestations of left ventricular hypertrophy (LVH) are common in aortic stenosis and arise as a result of the stenosis having placed a chronically high pressure load on the left ventricle (with LVH being the expected response to chronic pressure loads on the left ventricle no matter what the cause).
As noted above, the calcification process that occurs in aortic stenosis can progress to extend beyond the aortic valve and into the electrical conduction system of the heart. Evidence of this phenomenon may rarely include ECG patterns characteristic of certain types of heart block such as Left bundle branch block.
Cardiac chamber catheterization provides a definitive diagnosis, indicating severe stenosis in valve area of <1.0 cm2 (normally about 3 cm2). It can directly measure the pressure on both sides of the aortic valve. The pressure gradient may be used as a decision point for treatment. It is useful in symptomatic people before surgery. The standard for diagnosis of aortic stenosis is non-invasive testing with echocardiography. Cardiac catheterization is reserved for cases in which there is discrepancy between the clinical picture and non-invasive testing, due to risks inherent to crossing the aortic valve, such as stroke.
|Severity of aortic stenosis|
|Aortic valve area|
|Moderate||25 - 40||1.0 - 1.5|
|Very severe||>70||< 0.6|
Echocardiogram (heart ultrasound) is the best non-invasive way to evaluate the aortic valve anatomy and function.
The aortic valve area can be calculated non-invasively using echocardiographic flow velocities. Using the velocity of the blood through the valve, the pressure gradient across the valve can be calculated by the continuity equation or using the modified Bernoulli's equation:
Gradient = 4(velocity)² mmHg
A normal aortic valve has a gradient of only a few mmHg. A decreased valvular area causes increased pressure gradient, and these parameters are used to classify and grade the aortic stenosis as mild, moderate or severe. The pressure gradient can be abnormally low in the presence of mitral stenosis, heart failure, co-existent aortic regurgitation and also ischaemic heart disease (disease related to decreased blood supply and oxygen causing ischemia).
A chest X-ray can also assist in the diagnosis and provide clues as to the severity of the disease, showing the degree of calcification of the valve, and in a chronic condition, an enlarged left ventricle and atrium.
Treatment is generally not necessary in people without symptoms. In moderate cases, echocardiography is performed every 1–2 years to monitor the progression, possibly complemented with a cardiac stress test. In severe cases, echocardiography is performed every 3–6 months. In both moderate and mild cases, the person should immediately make a revisit or be admitted for inpatient care if any new related symptoms appear. There are no therapeutic options currently available to treat people with aortic valve stenosis; however, studies have indicated that the disease occurs as a result of active cellular processes, suggesting that targeting these processes may lead to viable therapeutic approaches.
In general, medical therapy has relatively poor efficacy in treating aortic stenosis. However, it may be useful to manage commonly coexisting conditions that correlate with aortic stenosis:
- Any angina is generally treated with beta-blockers and/or calcium blockers. Nitrates are contraindicated due to their potential to cause profound hypotension in aortic stenosis.
- Any hypertension is treated aggressively, but caution must be taken in administering beta-blockers.
- Any heart failure is generally treated with digoxin and diuretics, and, if not contraindicated, cautious administration of ACE inhibitors.
While observational studies demonstrated an association between lowered cholesterol with statins and decreased progression, a randomized clinical trial published in 2005 failed to find any effect on calcific aortic stenosis. A 2007 study did demonstrate a slowing of aortic stenosis with the statin rosuvastatin.
Aortic valve repairEdit
Aortic valve repair or aortic valve reconstruction describes the reconstruction of both form and function of the native and dysfunctioning aortic valve. Most frequently it is applied for the treatment of aortic regurgitation. It can also become necessary for the treatment of an aortic aneurysm, less frequently for congenital aortic stenosis.
Aortic valve replacementEdit
In adults, symptomatic severe aortic stenosis usually requires aortic valve replacement (AVR). While AVR has been the standard of care for aortic stenosis for several decades, currently aortic valve replacement approaches include open heart surgery, minimally invasive cardiac surgery (MICS) and minimally invasive catheter-based (percutaneous) aortic valve replacement. However, surgical aortic valve replacement is well studied and generally has a good and well established longer-term prognosis.
A diseased aortic valve is most commonly replaced using a surgical procedure with either a mechanical or a tissue valve. The procedure is done either in an open-heart surgical procedure or, in a smaller but growing number of cases, a minimally invasive cardiac surgery (MICS) procedure.
Transcatheter aortic valve replacementEdit
Globally more than 250,000 people have received transcatheter aortic valve replacement (TAVR). For people who are not candidates for surgical valve replacement and most patients who are older than 75, TAVR may be a suitable alternative.
For infants and children, balloon valvuloplasty, where a balloon is inflated to stretch the valve and allow greater flow, may also be effective. In adults, however, it is generally ineffective, as the valve tends to return to a stenosed state. The surgeon will make a small incision at the top of the person's leg and proceed to insert the balloon into the artery. The balloon is then advanced up to the valve and is inflated to stretch the valve open.
Acute decompensated heart failure due to AS may be temporarily managed by an intra-aortic balloon pump while pending surgery. In those with high blood pressure nitroprusside may be carefully used. Phenylephrine may be used in those with very low blood pressure.
If untreated, severe symptomatic aortic stenosis carries a poor prognosis with a 2-year mortality rate of 50-60% and a 3-year survival rate of less than 30%. Prognosis after aortic valve replacement for people who are younger than 65 is about five years less than that of the general population; for people older than 65 it is about the same.
Approximately 2% of people over the age of 65, 3% of people over age 75, and 4% percent of people over age 85 have aortic valve stenosis. The prevalence is increasing with the aging population in North America and Europe.
Risk factors known to influence disease progression of AS include lifestyle habits similar to those of coronary artery disease such as hypertension, advanced age, being male, hyperlipidemia, diabetes mellitus, cigarette smoking, metabolic syndrome, and end-stage kidney disease.
Aortic stenosis was first described by French physician Lazare Rivière in 1663.
People on bisphosphonates have less progression of aortic stenosis and some regressed. This finding led to multiple trials which are ongoing. Subsequent research has failed to confirm the initial positive result.
- Czarny, MJ; Resar, JR (2014). "Diagnosis and management of valvular aortic stenosis". Clinical Medicine Insights. Cardiology. 8 (Suppl 1): 15–24. doi:10.4137/CMC.S15716. PMC 4213201. PMID 25368539.
- Overgaard, CB; Dzavík, V (2 September 2008). "Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease". Circulation. 118 (10): 1047–56. doi:10.1161/CIRCULATIONAHA.107.728840. PMID 18765387.
- Manning WJ (October 2013). "Asymptomatic aortic stenosis in the elderly: a clinical review". JAMA. 310 (14): 1490–7. doi:10.1001/jama.2013.279194. PMID 24104373.
- Thaden, JJ; Nkomo, VT; Enriquez-Sarano, M (2014). "The global burden of aortic stenosis". Progress in Cardiovascular Diseases. 56 (6): 565–71. doi:10.1016/j.pcad.2014.02.006. PMID 24838132.
- Leopold JA (August 2012). "Cellular mechanisms of aortic valve calcification". Circulation: Cardiovascular Interventions. 5 (4): 605–14. doi:10.1161/CIRCINTERVENTIONS.112.971028. PMC 3427002. PMID 22896576.
- Rogers, FJ (November 2013). "Aortic stenosis: new thoughts on a cardiac disease of older people". Journal of the American Osteopathic Association. 113 (11): 820–828. doi:10.7556/jaoa.2013.057. PMID 24174503.
- Silverman, ME (April 1999). "A view from the millennium: the practice of cardiology circa 1950 and thereafter". Journal of the American College of Cardiology. 33 (5): 1141–51. doi:10.1016/s0735-1097(99)00027-3. PMID 10193710.
- Chapter 1: Diseases of the Cardiovascular system > Section: Valvular Heart Disease in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 978-0-7817-7153-5.[page needed]
- Blase A. Carabello. (2002). "Evaluation and management of patients with aortic stenosis". Circulation. 105 (15): 1746–1750. doi:10.1161/01.cir.0000015343.76143.13.
- Richards, Mark; Ikram, Hamid; Nicholls, M. Gary; Hamilton, Eric; Richards, Rosemary (1984). "Syncope in aortic valvular stenosis". The Lancet. 324 (8412): 1113–1116. doi:10.1016/S0140-6736(84)91555-1.
- Bertazzo S, Gentleman E, Cloyd KL, Chester AH, Yacoub MH, Stevens MM (June 2013). "Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification". Nature Materials. 12 (6): 576–83. Bibcode:2013NatMa..12..576B. doi:10.1038/nmat3627. PMC 5833942. PMID 23603848.
- Miller JD (June 2013). "Cardiovascular calcification: Orbicular origins". Nature Materials. 12 (6): 476–8. Bibcode:2013NatMa..12..476M. doi:10.1038/nmat3663. PMID 23695741.
- Figuinha, FC; Spina, GS; Tarasoutchi, F (March 2011). "Heyde's syndrome: case report and literature review". Arquivos Brasileiros de Cardiologia. 96 (3): e42–e45. doi:10.1590/S0066-782X2011000300017. PMID 21484065.
- Ricardo Zalaquett, Cristóbal Camplá, et al. (2005). "Cirugía reparadora de la válvula aórtica bicúspide insuficiente". Rev Méd Chile, 133(3): pp. 279-86. Archived 2013-11-03 at the Wayback Machine ISSN 0034-9887.
- VOC=VITIUM ORGANICUM CORDIS, a compendium of the Department of Cardiology at Uppsala Academic Hospital. By Per Kvidal September 1999, with revision by Erik Björklund May 2008
- Olszowska, M (November 2011). "Pathogenesis and pathophysiology of aortic valve stenosis in adults" (PDF). Polskie Archiwum Medcyny Wewnetrznej. 121 (11): 409–413. PMID 22129836. Archived (PDF) from the original on 2013-11-04.
- Lilly LS, ed. (2003). Pathophysiology of Heart Disease (3rd ed.). Lippincott Williams & Wilkins. ISBN 978-0-7817-4027-2.
- G. Morris, Innasimuthu A L, J.P. Fox, R.A. Perry; The association of heart valve diseases with a dominant left coronary circulation – European Heart Journal, 2009; 30:682
- Morris GM, Innasimuthu AL, Fox JP, Perry RA (May 2010). "The association of heart valve diseases with coronary artery dominance". The Journal of Heart Valve Disease. 19 (3): 389–93. PMID 20583404.
- Innasimuthu A L, Morris G, Rao G K, Perry R A; Left Dominant Coronary arterial system and Aortic stenosis: an association, cause or effect – Heart 2007; 93 (Suppl 1): A39.[verification needed]
- Etchells E, Bell C, Robb K (February 1997). "Does this patient have an abnormal systolic murmur?". JAMA. 277 (7): 564–71. doi:10.1001/jama.277.7.564. PMID 9032164.
- Lilly, Leonard S., ed. (2007). Pathophysiology of heart disease : a collaborative project of medical students and faculty (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 36. ISBN 978-0-7817-6321-9.
- Yale atlas of echocardiography Archived November 30, 2012, at the Wayback Machine
- Hutcheson JD, Aikawa E, Merryman WD (April 2014). "Potential drug targets for calcific aortic valve disease". Nature Reviews Cardiology. 11 (4): 218–31. doi:10.1038/nrcardio.2014.1. PMC 4263317. PMID 24445487.
- Rutherford SD, Braunwald E (1992). "Chronic ischaemic heart disease". In Braunwald E (ed.). Heart disease: A textbook of cardiovascular medicine (4th ed.). Philadelphia: WB Saunders. pp. 1292–364.
- Moura LM, Ramos SF, Zamorano JL, et al. (February 2007). "Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis". Journal of the American College of Cardiology. 49 (5): 554–61. doi:10.1016/j.jacc.2006.07.072. PMC 3951859. PMID 17276178.
- Hans-Joachim Schäfers: Current treatment of aortic regurgitation. UNI-MED Science, Bremen, London, Boston 2013, ISBN 978-3-8374-1406-6.
- Siemieniuk RA, Agoritsas T, Manja V, et al. (2016). "Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis". BMJ. 354: i5130. doi:10.1136/bmj.i5130. PMC 5040923. PMID 27683246. Archived from the original on 2016-10-05.
- Vandvik PO, Otto CM, Siemieniuk RA, Bagur R, Guyatt GH, Lytvyn L, Whitlock R, Vartdal T, Brieger D, Aertgeerts B, Price S, Foroutan F, Shapiro M, Mertz R, Spencer FA (2016). "Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline". BMJ. 354: i5085. doi:10.1136/bmj.i5085. PMID 27680583. Archived from the original on 2016-10-05.
- Foroutan F, Guyatt GH, O'Brien K, et al. (2016). "Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies". BMJ. 354: i5065. doi:10.1136/bmj.i5065. PMC 5040922. PMID 27683072. Archived from the original on 2016-10-05.
- Mayo Clinic > Aortic valve stenosis > Treatments and drugs Archived 2007-10-04 at the Wayback Machine Retrieved September 2010
- Christopher M. O'Connor (2005). Managing Acute Decompensated Heart Failure a Clinician's Guide to Diagnosis and Treatment. London: Informa Healthcare. p. 406. ISBN 9780203421345. Archived from the original on 2015-04-02.
- Spaccarotella C, Mongiardo A, Indolfi C (2011). "Pathophysiology of aortic stenosis and approach to treatment with percutaneous valve implantation". Circulation Journal. 75 (1): 11–19. doi:10.1253/circj.CJ-10-1105. PMID 21178291.
- Stewart BF, Siscovick D, Lind BK, et al. (March 1997). "Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study". Journal of the American College of Cardiology. 29 (3): 630–4. doi:10.1016/S0735-1097(96)00563-3. PMID 9060903.
- clinical Anesthesiology by Edward Morgan[page needed]
- Innasimuthu AL, Katz WE (January 2011). "Effect of bisphosphonates on the progression of degenerative aortic stenosis". Echocardiography. 28 (1): 1–7. doi:10.1111/j.1540-8175.2010.01256.x. PMID 20678125.
- Nathaniel S, Saligram S, Innasimuthu AL (June 2010). "Aortic stenosis: An update". World Journal of Cardiology. 2 (6): 135–9. doi:10.4330/wjc.v2.i6.135. PMC 2999052. PMID 21160731.
- Aksoy O, Cam A, Goel SS, et al. (April 2012). "Do bisphosphonates slow the progression of aortic stenosis?". Journal of the American College of Cardiology. 59 (16): 1452–9. doi:10.1016/j.jacc.2012.01.024. PMID 22497825.
- Bonow, Robert O.; Brown, Alan S.; Gillam, Linda D.; Kapadia, Samir R.; Kavinsky, Clifford J.; Lindman, Brian R.; Mack, Michael J.; Thourani, Vinod H. (October 2017). "ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for the Treatment of Patients With Severe Aortic Stenosis". Journal of the American College of Cardiology. 70 (20): 2566–2598. doi:10.1016/j.jacc.2017.09.018. PMID 29054308.